RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
SK Biopharmaceuticals Co Stock

SK Biopharmaceuticals Co Revenue 2024

SK Biopharmaceuticals Co Revenue

518.23 B KRW

Ticker

326030.KS

ISIN

KR7326030004

In 2024, SK Biopharmaceuticals Co's sales reached 518.23 B KRW, a 46.03% difference from the 354.89 B KRW sales recorded in the previous year.

The SK Biopharmaceuticals Co Revenue history

YEARREVENUE (undefined KRW)GROSS MARGIN (%)
2026e826.7338,80
2025e661.8348,47
2024e518.2361,90
2023354.8990,40
2022246.1884,66
2021418.6494,66
20202692,41
2019123.8599,58
20181.1100,00
201785.324,19

SK Biopharmaceuticals Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into SK Biopharmaceuticals Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by SK Biopharmaceuticals Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects SK Biopharmaceuticals Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of SK Biopharmaceuticals Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into SK Biopharmaceuticals Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing SK Biopharmaceuticals Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on SK Biopharmaceuticals Co’s growth potential.

SK Biopharmaceuticals Co Revenue, EBIT and net profit per share

DateSK Biopharmaceuticals Co RevenueSK Biopharmaceuticals Co EBITSK Biopharmaceuticals Co Net Income
2026e826.73 B undefined284.67 B undefined254.19 B undefined
2025e661.83 B undefined152.33 B undefined144.5 B undefined
2024e518.23 B undefined54.1 B undefined66.9 B undefined
2023354.89 B undefined-37.52 B undefined-32.88 B undefined
2022246.18 B undefined-131.08 B undefined-139.43 B undefined
2021418.64 B undefined94.96 B undefined64.85 B undefined
202026 B undefined-239.5 B undefined-247.41 B undefined
2019123.85 B undefined-79.26 B undefined-71.52 B undefined
20181.1 B undefined-139.1 B undefined-138.1 B undefined
201785.32 B undefined-97.97 B undefined-97.65 B undefined

SK Biopharmaceuticals Co stock margins

The SK Biopharmaceuticals Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of SK Biopharmaceuticals Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for SK Biopharmaceuticals Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the SK Biopharmaceuticals Co's sales revenue. A higher gross margin percentage indicates that the SK Biopharmaceuticals Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the SK Biopharmaceuticals Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the SK Biopharmaceuticals Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the SK Biopharmaceuticals Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the SK Biopharmaceuticals Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the SK Biopharmaceuticals Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

SK Biopharmaceuticals Co Margin History

SK Biopharmaceuticals Co Gross marginSK Biopharmaceuticals Co Profit marginSK Biopharmaceuticals Co EBIT marginSK Biopharmaceuticals Co Profit margin
2026e90.4 %34.43 %30.75 %
2025e90.4 %23.02 %21.83 %
2024e90.4 %10.44 %12.91 %
202390.4 %-10.57 %-9.27 %
202284.66 %-53.24 %-56.64 %
202194.66 %22.68 %15.49 %
202092.41 %-921.18 %-951.63 %
201999.58 %-63.99 %-57.75 %
2018100 %-12,657.23 %-12,565.61 %
20174.19 %-114.84 %-114.46 %

SK Biopharmaceuticals Co Aktienanalyse

What does SK Biopharmaceuticals Co do?

SK Biopharmaceuticals Co Ltd is a leading bio-pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for central nervous system (CNS) disorders. The company is headquartered in South Korea and has been listed on the Korean Stock Exchange since 2014. The history of SK Biopharmaceuticals dates back to 1998 when it was established as a joint venture between SK Group and Hanmi Pharmaceutical. SK Biopharmaceuticals works closely with its parent companies, utilizing their extensive experience and infrastructure in research and development, production, and marketing. The business model of SK Biopharmaceuticals is based on creating value through research and development of drugs for the global market. Within this framework, the company develops innovative bio-pharmaceutical solutions for a range of therapeutic areas, particularly CNS disorders. SK Biopharmaceuticals strives to establish a strong presence in the global bio-pharmaceutical market through partnerships and strategic alliances with other companies. SK Biopharmaceuticals is organized into various divisions, including research and development, production, sales, and marketing. Each of these divisions is tailored to meet the needs of customers and patients to ensure optimal access to medications. The company has various products with different indications on the market worldwide, including the anticonvulsant Brivaracetam, which is approved for the treatment of epilepsy. Brivaracetam is a fast-acting, highly selective, and potent anticonvulsant that demonstrates significant reduction in seizure frequency in patients with epilepsy. SK Biopharmaceuticals continuously works to expand its product portfolio and develop innovative solutions for the treatment of neurological disorders. In addition to drug development for the global market, SK Biopharmaceuticals is also active in the field of biotechnology. The company is committed to harnessing the latest advancements in biotechnology and genomics to support the discovery, development, and commercialization of medications. SK Biopharmaceuticals has established itself as a leading company in the bio-pharmaceutical industry. The company is dedicated to excellence in research, development, and marketing of innovative solutions for the treatment of neurological disorders. With a strong global presence and a dedicated workforce, SK Biopharmaceuticals is well-positioned to further expand its position as a pioneer in the bio-pharmaceutical industry. SK Biopharmaceuticals Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding SK Biopharmaceuticals Co's Sales Figures

The sales figures of SK Biopharmaceuticals Co originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing SK Biopharmaceuticals Co’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize SK Biopharmaceuticals Co's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in SK Biopharmaceuticals Co’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about SK Biopharmaceuticals Co stock

How much revenue did SK Biopharmaceuticals Co generate this year?

SK Biopharmaceuticals Co has achieved a revenue of 518.23 B KRW this year.

How much was the turnover of the company SK Biopharmaceuticals Co compared to the previous year?

The revenue of SK Biopharmaceuticals Co has increased by 46.03% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of SK Biopharmaceuticals Co?

The revenue of SK Biopharmaceuticals Co is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of SK Biopharmaceuticals Co measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of SK Biopharmaceuticals Co so important for investors?

The revenue of SK Biopharmaceuticals Co is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does SK Biopharmaceuticals Co pay?

Over the past 12 months, SK Biopharmaceuticals Co paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, SK Biopharmaceuticals Co is expected to pay a dividend of 0 KRW.

What is the dividend yield of SK Biopharmaceuticals Co?

The current dividend yield of SK Biopharmaceuticals Co is .

When does SK Biopharmaceuticals Co pay dividends?

SK Biopharmaceuticals Co pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of SK Biopharmaceuticals Co?

SK Biopharmaceuticals Co paid dividends every year for the past 0 years.

What is the dividend of SK Biopharmaceuticals Co?

For the upcoming 12 months, dividends amounting to 0 KRW are expected. This corresponds to a dividend yield of 0 %.

In which sector is SK Biopharmaceuticals Co located?

SK Biopharmaceuticals Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von SK Biopharmaceuticals Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of SK Biopharmaceuticals Co from 10/1/2024 amounting to 0 KRW, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did SK Biopharmaceuticals Co pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of SK Biopharmaceuticals Co in the year 2023?

In the year 2023, SK Biopharmaceuticals Co distributed 0 KRW as dividends.

In which currency does SK Biopharmaceuticals Co pay out the dividend?

The dividends of SK Biopharmaceuticals Co are distributed in KRW.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von SK Biopharmaceuticals Co

Our stock analysis for SK Biopharmaceuticals Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SK Biopharmaceuticals Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.